Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Genome-wide analysis of RNA-binding protein PSF-associated transcripts in prostate cancer

PROVIDER: PRJNA369120 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5211010.fastq.gz	Fastqsanger.gz
	SRR5211020.fastq.gz	Fastqsanger.gz
	SRR5211011.fastq.gz	Fastqsanger.gz
	SRR5211021.fastq.gz	Fastqsanger.gz
	SRR5211012.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

Genome wide mapping of PSF binding sites in prostate cancer cells

Project description:Prostate cancer is the most common cancer in men and AR downstream signalings promote prostate cancer cell proliferation. We identified androgen-regulated long non-coding RNA, CTBP1-AS, located in the antisese region of CTBP1 gene. CTBP1-AS activate AR signaling by epigenetically repress AR-associated cofactors such as CTBP1 by interactign with RNA-binding protein PSF and recruiting HDAC complex to the target promoters. In order investigated the PSF target genes, we performed ChIP-seq analysis of PSF binding sites in prostate cancer cell line, LNCaP cells. We identified androgen dependent PSF binding regions in prostate cancer cell genome. We observed PSF bindings around the promoters of androgen repressed genes such as CTBP1, p53 and SMAD3. ChIP-sequence analysis of PSF binding sites in prostate cancer cells

2014-01-01 | E-GEOD-45124 | biostudies-arrayexpress

Genome wide mapping of PSF binding sites in prostate cancer cells

2014-01-01 | GSE45124 | GEO

Modulation of PSF binding property at RNA level by small molecule treatment in prostate cancer

Project description:Prostate cancer is the most common cancer in men and androgen receptor (AR) downstream signalings promote prostate cancer cell proliferation. PSF is a RNA binding protein which is involved in AR signaling.To investigate the effect of samll molecule, No.10-3, on the RNA binding ability of PSF, we performed RNA immunoprecipitation (RIP) sequence analysis in AR positive prostate cancer cell line long term androgen deprivation (LTAD) cells to explore the differences of PSF function to associate with RNAs in prostate cancer cells.

2021-05-01 | GSE169139 | GEO

Analysis of RNA-binding protein PSF- and NONO-associated transcripts in breast cancer

Project description:Analysis of RNA-binding protein PSF- and NONO-associated transcripts in breast cancer

| PRJNA551436 | ENA

Effects of PSF and CTBP1-AS knockdown in prostate cancer cell lines

Project description:Prostate cancer is the most common cancer in men and Androgen receptor (AR) downstream signalings promote prostate cancer cell proliferation. We identified androgen-regulated long non-coding RNA, CTBP1-AS, located in the antisese region of CTBP1 gene. CTBP1-AS activate AR signaling by epigenetically repress AR-associated cofactors such as CTBP1 by interactign with RNA-binding protein PSF and recruiting HDAC complex to the target promoters. In order to investigate the CTBP1-AS and PSF function in prostate cancer cells, we performed gene expression in AR-positive prostate cancer cell lines after siPSF or siCTBP1-AS treatment. We also treated cells with vehicle or androgen to analyzed the effects of CTBP1-AS and PSF on AR function. Observation of androgen dependent gene expression changes after treatmet with siRNAs targeting CTBP1-AS and PSF with microarray.

2014-01-01 | E-GEOD-44264 | biostudies-arrayexpress

Genome-wide analysis of RNA-binding protein PSF-associated transcripts in prostate cancer

Project description:Prostate cancer is the most common cancer in men and androgen receptor (AR) downstream signalings promote prostate cancer cell proliferation. PSF is an RNA-binding protein which is involved in AR signaling. To investigate the role of PSF, we performed RNA immunoprecipitation (RIP) and crosslinking immunoprecipitation (CLIP) sequence analysis in AR-positive prostate cancer cell line, LNCaP. In addition, we used hormone-refractory prostate cancer model cells 22Rv1 and long term androgen deprivation (LTAD) cells to explore the differences of PSF function in prostate cancer progression.

2017-12-24 | GSE94243 | GEO

Effects of PSF inhibitors in castration-resistant prostate cancer cells

Project description:Prostate cancer is the most common cancer in men and AR downstream signalings promote prostate cancer cell proliferation. Although initially hormone-deprovation therapy is effective to inhibit cancer progression, most of cancers relapse as castration-resistant prostate cancer (CRPC). RNA binding protein PSF is upregulated in CRPC tissues comparedd with hormone-sensitive prostate cancer. Therefore, we examined the effect of newly developed small molecules targeting PSF in CRPC cells. In order to investigate the effect of PSF inhibiton in CRPC cells, we performed gene expression analysis in AR-negative CRPC cell line, DU145. We treated cells with vehicle, No.10-3, or C-30, which are supposed to inhibit PSF function.

2024-09-01 | GSE243001 | GEO

Effects of PSF and CTBP1-AS knockdown in prostate cancer cell lines

2014-01-01 | GSE44264 | GEO

Effects of PSF inhibitors on histone acetylation in prostate cancer cells [ChIP-seq]

Project description:Prostate cancer is the most common cancer in men and AR downstream signalings promote prostate cancer cell proliferation. Although initially hormone-deprovation therapy is effective to inhibit cancer progression, most of cancers relapse as castration-resistant prostate cancer (CRPC). PSF is one of RNA binding proteins associated with prostate cancer progression. In this study, we examined the effect of small molecule treatment interacting with PSF on the histone acetylation status in CRPC cells.

2021-05-01 | GSE155803 | GEO

Investigation of PSF and p53 binding sites in prostate ccancer cells

Project description:Proline- and glutamine-rich (PSF) has been identified as an important driver of aggressive cancers, in which PSF-RNA interactions promotes the expression of numerous oncogenic transcripts by modulating epigenetic and splicing systems. To develop small compounds targeting PSF as next generation therapeutic agents for hormone therapy refractory cancers, we performed small molecule library screen and identified the compound designated as No.10-3 as a potent PSF inhibitor. We further describe another small molecule C-30, an improved analog of No.10-3. PSF inhibits p53 epression in prostate cancer cells by epigenetic regulation. We then performed ChIP-seq analysis to determined PSF and p53 binding regions.

2024-09-01 | GSE244040 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data